middle.news
Botanix Pharmaceuticals Launches Sofdra, Eyes Revenue Surge in 2025
9:32am on Friday 31st of January, 2025 AEDT
•
Pharmaceuticals
Read Story
Botanix Pharmaceuticals Launches Sofdra, Eyes Revenue Surge in 2025
9:32am on Friday 31st of January, 2025 AEDT
Key Points
First Sofdra prescriptions issued and 100% refill rate achieved
Full commercial launch underway with 27 trained territory managers
Contracts secured with key US commercial and government payers covering 247 million lives
Q1 2025 expected to deliver first commercial revenue quarter, with Q2 revenue ramp anticipated
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Botanix Pharmaceuticals (ASX:BOT)
OPEN ARTICLE